[{"orgOrder":0,"company":"FibroBiologics","sponsor":"Yorkville","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"CYPS317","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"FibroBiologics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Yorkville","highestDevelopmentStatusID":"4","companyTruncated":"FibroBiologics \/ Yorkville"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"CYWC628","moa":"Undisclosed","graph1":"Podiatry","graph2":"Preclinical","graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ FibroBiologics","highestDevelopmentStatusID":"4","companyTruncated":"FibroBiologics \/ FibroBiologics"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tolerogenic Fibroblasts","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroBiologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FibroBiologics \/ Undisclosed"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FibroBiologics \/ Undisclosed"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Fibroblast Spheroids","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"FibroBiologics \/ Undisclosed"}]